Psychiatric, nonmotor aspects of Parkinson's disease

Handbook of Clinical Neurology

Volumn 106, Issue , 2012, Pages 477-490

  Müller, Thomas ^a   Gerlach, Manfred ^b   Youdim, Moussa B H ^c   Riederer, Peter ^b  

^a ST JOSEF HOSPITAL   (Germany)

^b UNIVERSITY OF WÜRZBURG   (Germany)

^c TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84861160266     PISSN: 00729752     EISSN: None     Source Type: Book Series    
DOI: 10.1016/B978-0-444-52002-9.00028-0     Document Type: Chapter

References (142)

1. Aarsland D., Tandberg E., Larsen J.P., et al. Frequency of dementia in Parkinson disease. Arch Neurol 1996, 53:538-542.
2. Aarsland D., Ballard C., Walker Z., et al. Memantine in patients with Parkinson's disease dementia or dementia with Lewy bodies: a double-blind, placebo-controlled, multicentre trial. Lancet Neurol 2009, 8:613-618.
3. Alberts J.L., Voelcker-Rehage C., Hallahan K., et al. Bilateral subthalamic stimulation impairs cognitive-motor performance in Parkinson's disease patients. Brain 2008, 131:3348-3360.
4. Andreu N., Chale J.J., Senard J.M., et al. L-Dopa-induced sedation: a double-blind cross-over controlled study versus triazolam and placebo in healthy volunteers. Clin Neuropharmacol 1999, 22:15-23.
5. Arnsten A.F., Li B.M. Neurobiology of executive functions: catecholamine influences on prefrontal cortical functions. Biol Psychiatry 2005, 57:1377-1384.
6. Baas H., Beiske A.G., Ghika J., et al. Catechol-O-methyltransferase inhibition with tolcapone reduces the " wearing off" phenomenon and levodopa requirements in fluctuating parkinsonian patients. J Neurol Neurosurg Psychiatry 1997, 63:421-428.
7. Barone P., Burn D.J., van Laar T., et al. Rivastigmine versus placebo in hyperhomocysteinemic Parkinson's disease dementia patients. Mov Disord 2008, 23:1532-1540.
8. Behnke S., Schroeder U., Dillmann U., et al. Hyperechogenicity of the substantia nigra in healthy controls is related to MRI changes and to neuronal loss as determined by F-Dopa PET. Neuroimage 2009, 47:1237-1243.
9. Ben Shlomo Y., Marmot M.G. Survival and cause of death in a cohort of patients with parkinsonism: possible clues to aetiology?. J Neurol Neurosurg Psychiatry 1995, 58:293-299.
10. Birkmayer W., Hornykiewicz O. The L-3,4-dioxyphenylalanine (DOPA)-effect in Parkinson-akinesia. Wien Klin Wochenschr 1961, 73:787-788.
11. Birkmayer W., Mentasti M. Further experimental studies on the catecholamine metabolism in extrapyramidal diseases (Parkinson and chorea syndromes). Arch Psychiatr Nervenkr 1967, 210:29-35.
12. Block G., Liss C., Reines S., et al. Comparison of immediate-release and controlled release carbidopa/levodopa in Parkinson's disease. A multicenter 5-year study. The CR First Study Group. Eur Neurol 1997, 37:23-27.
13. Braak H., Braak E., Yilmazer D., et al. Nigral and extranigral pathology in Parkinson's disease. J Neural Transm Suppl 1995, 46:15-31.
14. Braak H., Rub U., Gai W.P., et al. Idiopathic Parkinson's disease: possible routes by which vulnerable neuronal types may be subject to neuroinvasion by an unknown pathogen. J Neural Transm 2003, 110:517-536.
15. Burke R.E., Dauer W.T., Vonsattel J.P. A critical evaluation of the Braak staging scheme for Parkinson's disease. Ann Neurol 2008, 64:485-491.
16. Burn D.J., Troster A.I. Neuropsychiatric complications of medical and surgical therapies for Parkinson's disease. J Geriatr Psychiatry Neurol 2004, 17:172-180.
17. Ceravolo R., Piccini P., Bailey D.L., et al. 18F-dopa PET evidence that tolcapone acts as a central COMT inhibitor in Parkinson's disease. Synapse 2002, 43:201-207.
18. Chase T.N., Oh J.D. Striatal mechanisms and pathogenesis of parkinsonian signs and motor complications. Ann Neurol 2000, 47:S122-S129.
19. Checkoway H., Nelson L.M. Epidemiologic approaches to the study of Parkinson's disease etiology. Epidemiology 1999, 10:327-336.
20. Cote L. Depression: impact and management by the patient and family. Neurology 1999, 52:S7-S9.
21. Cotzias G.C., Van Woert M.H., Schiffer L.M. Aromatic amino acids and modification of parkinsonism. N Engl J Med 1967, 276:374-379.
22. Cotzias G.C., Papavasiliou P.S., Gellene R. Modification of Parkinsonism - chronic treatment with L-dopa. N Engl J Med 1969, 280:337-345.
23. de Rijk M.C., Tzourio C., Breteler M.M., et al. Prevalence of parkinsonism and Parkinson's disease in Europe: the EUROPARKINSON Collaborative Study. European Community Concerted Action on the Epidemiology of Parkinson's disease. J Neurol Neurosurg Psychiatry 1997, 62:10-15.
24. de Rijk M.C., Launer L.J., Berger K., et al. Prevalence of Parkinson's disease in Europe: a collaborative study of population-based cohorts. Neurologic Diseases in the Elderly Research Group. Neurology 2000, 54:S21-S23.
25. Deuschl G., Schade-Brittinger C., Krack P., et al. A randomized trial of deep-brain stimulation for Parkinson's disease. N Engl J Med 2006, 355:896-908.
26. Doty R.L. Influence of age and age-related diseases on olfactory function. Ann N Y Acad Sci 1989, 561:76-86.
27. Durif F. Treating and preventing levodopa-induced dyskinesias: current and future strategies. Drugs Aging 1999, 14:337-345.
28. Emre M. Dementia in Parkinson's disease: cause and treatment. Curr Opin Neurol 2004, 17:399-404.
29. Emre M., Aarsland D., Albanese A., et al. Rivastigmine for dementia associated with Parkinson's disease. N Engl J Med 2004, 351:2509-2518.
30. Evans A.H., Lees A.J. Dopamine dysregulation syndrome in Parkinson's disease. Curr Opin Neurol 2004, 17:393-398.
31. Factor S.A., Brown D. Clozapine prevents recurrence of psychosis in Parkinson's disease. Mov Disord 1992, 7:125-131.
32. Factor S.A., Feustel P.J., Friedman J.H., et al. Longitudinal outcome of Parkinson's disease patients with psychosis. Neurology 2003, 60:1756-1761.
33. Fahn S., Oakes D., Shoulson I., et al. Levodopa and the progression of Parkinson's disease. N Engl J Med 2004, 351:2498-2508.
34. Fox M.J. Lucky Man: A Memoir 2003, Hyperion, New York, 2002.
35. Fronczek R., Overeem S., Lee S.Y., et al. Hypocretin (orexin) loss in Parkinson's disease. Brain 2007, 130:1577-1585.
36. Gerlach M., Riederer P.F. Time sequences of dopaminergic cell death in Parkinson's disease: indications for neuroprotective studies. Adv Neurol 1999, 80:219-225.
37. Gerlach M., Blum-Degen D., Lan J., et al. Nitric oxide in the pathogenesis of Parkinson's disease. Adv Neurol 1999, 80:239-245.
38. Gershanik O., Emre M., Bernhard G., et al. Efficacy and safety of levodopa with entacapone in Parkinson's disease patients suboptimally controlled with levodopa alone, in daily clinical practice: an international, multicentre, open-label study. Prog Neuropsychopharmacol Biol Psychiatry 2003, 27:963-971.
39. Giladi N., Shabtai H., Gurevich T., et al. Rivastigmine (Exelon) for dementia in patients with Parkinson's disease. Acta Neurol Scand 2003, 108:368-373.
40. Godau J., Berg D. Role of transcranial ultrasound in the diagnosis of movement disorders. Neuroimaging Clin N Am 2010, 20:87-101.
41. Goetze O., Wieczorek J., Mueller T., et al. Impaired gastric emptying of a solid test meal in patients with Parkinson's disease using 13C-sodium octanoate breath test. Neurosci Lett 2005, 375:170-173.
42. Goetze O., Nikodem A.B., Wiezcorek J., et al. Predictors of gastric emptying in Parkinson's disease. Neurogastroenterol Motil 2006, 18:369-375.
43. Gorell J.M., Johnson C.C., Rybicki B.A. Parkinson's disease and its comorbid disorders: an analysis of Michigan mortality data, 1970 to 1990. Neurology 1994, 44:1865-1868.
44. Halpern C.H., Rick J.H., Danish S.F., et al. Cognition following bilateral deep brain stimulation surgery of the subthalamic nucleus for Parkinson's disease. Int J Geriatr Psychiatry 2009, 24:443-451.
45. Hassin-Baer S., Cohen O., Vakil E., et al. Plasma homocysteine levels and Parkinson disease: disease progression, carotid intima-media thickness and neuropsychiatric complications. Clin Neuropharmacol 2006, 29:305-311.
46. Hawkes C.H., Del Tredici K., Braak H. Parkinson's disease: a dual-hit hypothesis. Neuropathol Appl Neurobiol 2007, 33:599-614.
47. Hirsch E.C., Hunot S., Damier P., et al. Glial cells and inflammation in Parkinson's disease: a role in neurodegeneration?. Ann Neurol 1998, 44:S115-S120.
48. Hogl B., Saletu M., Brandauer E., et al. Modafinil for the treatment of daytime sleepiness in Parkinson's disease: a double-blind, randomized, crossover, placebo-controlled polygraphic trial. Sleep 2002, 25:905-909.
49. Hornykiewicz O. Biochemical aspects of Parkinson's disease. Neurology 1998, 51:S2-S9.
50. Horowski R., Horowski L., Vogel S., et al. An essay on Wilhelm von Humboldt and the shaking palsy: first comprehensive description of Parkinson's disease by a patient. Neurology 1995, 45:565-568.
51. Hughes A.J., Daniel S.E., Kilford L., et al. Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry 1992, 55:181-184.
52. Isobe C., Murata T., Sato C., et al. Increase of total homocysteine concentration in cerebrospinal fluid in patients with Alzheimer's disease and Parkinson's disease. Life Sci 2005, 77:1836-1843.
53. Jenner P. Pathophysiology and biochemistry of dyskinesia: clues for the development of non-dopaminergic treatments. J Neurol 2000, 247:II43-II50.
54. Jenner P. Avoidance of dyskinesia: preclinical evidence for continuous dopaminergic stimulation. Neurology 2004, 62:S47-S55.
55. Jenner P., Olanow C.W. Oxidative stress and the pathogenesis of Parkinson's disease. Neurology 1996, 47:S161-S170.
56. Juncos J.L., Roberts V.J., Evatt M.L., et al. Quetiapine improves psychotic symptoms and cognition in Parkinson's disease. Mov Disord 2004, 19:29-35.
57. Juri C., Viviani P., Chana P. Features associated with the development of non-motor manifestations in Parkinson's disease. Arq Neuropsiquiatr 2008, 66:22-25.
58. Kent A.P., Stern G.M., Webster R.A. The effect of benserazide on the peripheral and central distribution and metabolism of levodopa after acute and chronic administration in the rat. Br J Pharmacol 1990, 100:743-748.
59. Kurlan R., Rothfield K.P., Woodward W.R., et al. Erratic gastric emptying of levodopa may cause " random" fluctuations of parkinsonian mobility. Neurology 1988, 38:419-421.
60. Kuroki T., Nagao N., Nakahara T. Neuropharmacology of second-generation antipsychotic drugs: a validity of the serotonin-dopamine hypothesis. Prog Brain Res 2008, 172:199-212.
61. Lange K.W., Kornhuber J., Riederer P. Dopamine/glutamate interactions in Parkinson's disease. Neurosci Biobehav Rev 1997, 21:393-400.
62. Lauterbach E.C. The neuropsychiatry of Parkinson's disease and related disorders. Psychiatr Clin North Am 2004, 27:801-825.
63. Lee E.S., Chen H., Soliman K.F., et al. Effects of homocysteine on the dopaminergic system and behavior in rodents. Neurotoxicology 2005, 26:361-371.
64. Leroi I., Brandt J., Reich S.G., et al. Randomized placebo-controlled trial of donepezil in cognitive impairment in Parkinson's disease. Int J Geriatr Psychiatry 2004, 19:1-8.
65. Leroi I., Overshott R., Byrne E.J., et al. Randomized controlled trial of memantine in dementia associated with Parkinson's disease. Mov Disord 2009, 24:1217-1221.
66. Lipton S.A., Kim W.K., Choi Y.B., et al. Neurotoxicity associated with dual actions of homocysteine at the N- methyl-D-aspartate receptor. Proc Natl Acad Sci U S A 1997, 94:5923-5928.
67. Litvinenko I.V., Odinak M.M., Mogil'naya V.I., et al. Use of memantine (Akatinol) for the correction of cognitive impairments in Parkinson's disease complicated by dementia. Neurosci Behav Physiol 2010, 40:149-155.
68. Lyons K.E., Pahwa R. Effects of bilateral subthalamic nucleus stimulation on sleep, daytime sleepiness, and early morning dystonia in patients with Parkinson disease. J Neurosurg 2006, 104:502-505.
69. Maetzler W., Liepelt I., Berg D. Progression of Parkinson's disease in the clinical phase: potential markers. Lancet Neurol 2009, 8:1158-1171.
70. Marras C., Tanner C.M. Epidemiology of Parkinson's disease. Movement Disorders: Neurologic Principles and Practice 2004, McGraw Hill, New York, pp. 177-195. 2nd edn. R.L. Watts, W.C. Koller (Eds.).
71. Matheson A.J., Lamb H.M. Quetiapine - a review of its clinical potential in the management of psychotic symptoms in Parkinson's disease. CNS Drugs 2000, 14:157-172.
72. Meiler B., Andrich J., Müller T. Rapid switch from oral antiparkinsonian combination drug therapy to duodenal levodopa infusion. Mov Disord 2008, 23:145-146.
73. Miller J.W., Selhub J., Nadeau M.R., et al. Effect of L-dopa on plasma homocysteine in PD patients: relationship to B-vitamin status. Neurology 2003, 60:1125-1129.
74. Moller J.C., Oertel W.H., Koster J., et al. Long-term efficacy and safety of pramipexole in advanced Parkinson's disease: results from a European multicenter trial. Mov Disord 2005, 20:602-610.
75. Morelli M., Carta A.R., Jenner P. Adenosine A2A receptors and Parkinson's disease. Handb Exp Pharmacol 2009, 589-615.
76. Müller T. Dopaminergic substitution in Parkinson's disease. Expert Opin Pharmacother 2002, 3:1393-1403.
77. Müller T. Drug treatment of non-motor symptoms in Parkinson's disease. Expert Opin Pharmacother 2002, 3:381-388.
78. Müller T. Mood disorders in early Parkinson's disease. Curr Opin Psychiatry 2004, 17:191-196.
79. Müller T. Role of homocysteine in the treatment of Parkinson's disease. Expert Rev Neurother 2008, 8:957-967.
80. Müller T. Levodopa/carbidopa and entacapone in the treatment of Parkinson's disease: efficacy, safety and patient preference. Patient Prefer Adherence 2009, 3:51-59.
81. Müller T. Possible treatment concepts for the levodopa-related hyperhomocysteinemia. Cardiovasc Psychiatry Neurol 2009, 2009. 969752.
82. Müller T., Kuhn W. Tolcapone decreases plasma levels of S-adenosyl-L-homocysteine and homocysteine in treated Parkinson's disease patients. Eur J Clin Pharmacol 2006, 62:447-450.
83. Müller T., Kuhn W. Cysteine elevation in levodopa-treated patients with Parkinson's disease. Mov Disord 2009, 24:929-932.
84. Müller T., Kuhn W. Homocysteine levels after acute levodopa intake in patients with Parkinson's disease. Mov Disord 2009, 24:1339-1343.
85. Müller T., Muhlack S. Peripheral COMT inhibition prevents levodopa associated homocysteine increase. J Neural Transm 2009, 116:1253-1256.
86. Müller T., Woitalla D., Saft C., et al. Levodopa in plasma correlates with body weight of parkinsonian patients. Parkinsonism Relat Disord 2000, 6:171-173.
87. Müller T., Woitalla D., Schulz D., et al. Tolcapone increases maximum concentration of levodopa. J Neural Transm 2000, 107:113-119.
88. Müller T., Benz S., Bornke C. Delay of simple reaction time after levodopa intake. Clin Neurophysiol 2001, 112:2133-2137.
89. Müller T., Benz S., Bornke C., et al. Repeated rating improves value of diagnostic dopaminergic challenge tests in Parkinson's disease. J Neural Transm 2003, 110:603-609.
90. Müller T., Voss B., Hellwig K., et al. Treatment benefit correlates with increase of daily drug costs in Parkinson's disease clinics. NeuroRehabilitation 2003, 18:271-275.
91. Müller T., Renger K., Kuhn W. Levodopa associated homocysteine increase and sural axonal neurodegeneration. Arch Neurol 2004, 61:657-660.
92. Müller T., Ander L., Kolf K., et al. Comparison of 200 mg retarded release levodopa/carbidopa - with 150 mg levodopa/carbidopa/entacapone application: pharmacokinetics and efficacy in patients with Parkinson's disease. J Neural Transm 2007, 114:1457-1462.
93. Nakaso K., Yasui K., Kowa H., et al. Hypertrophy of IMC of carotid artery in Parkinson's disease is associated with L-DOPA, homocysteine, and MTHFR genotype. J Neurol Sci 2003, 207:19-23.
94. Nutt J.G., Wooten G.F. Diagnosis and initial management of Parkinson's disease. N Engl J Med 2005, 353:1021-1027.
95. Nyholm D. Pharmacokinetic optimisation in the treatment of Parkinson's disease: an update. Clin Pharmacokinet 2006, 45:109-136.
96. Obeso J.A., Olanow C.W., Nutt J.G. Levodopa motor complications in Parkinson's disease. Trends Neurosci 2000, 23:S2-S7.
97. Ogawa N. Factors affecting levodopa effects in Parkinson's disease. Acta Med Okayama 2000, 54:95-101.
98. Olanow C.W., Obeso J.A. Pulsatile stimulation of dopamine receptors and levodopa-induced motor complications in Parkinson's disease: implications for the early use of COMT inhibitors. Neurology 2000, 55:S72-S77.
99. Olanow C.W., Stocchi F. COMT inhibitors in Parkinson's disease: can they prevent and/or reverse levodopa-induced motor complications?. Neurology 2004, 62:S72-S81.
100. Olanow C.W., Schapira A.H., Roth T. Falling asleep at the wheel: motor vehicle mishaps in people taking pramipexole and ropinirole [letter; comment]. Neurology 2000, 54:274-277.
101. Olanow C.W., Kieburtz K., Stern M., et al. Double-blind, placebo-controlled study of entacapone in levodopa-treated patients with stable Parkinson disease. Arch Neurol 2004, 61:1563-1568.
102. O'Suilleabhain P.E., Sung V., Hernandez C., et al. Elevated plasma homocysteine level in patients with Parkinson disease: motor, affective, and cognitive associations. Arch Neurol 2004, 61:865-868.
103. Pahwa R., Stacy M.A., Factor S.A., et al. Ropinirole 24-hour prolonged release: randomized, controlled study in advanced Parkinson disease. Neurology 2007, 68:1108-1115.
104. Parkinson J. An Essay on the Shaking Palsy 1817, Sherwood Neely and Jones, London.
105. Poewe W.H., Deuschl G., Gordin A., et al. Efficacy and safety of entacapone in Parkinson's disease patients with suboptimal levodopa response: a 6-month randomized placebo-controlled double-blind study in Germany and Austria (Celomen study). Acta Neurol Scand 2002, 105:245-255.
106. Postuma R.B., Lang A.E., Massicotte-Marquez J., et al. Potential early markers of Parkinson disease in idiopathic REM sleep behavior disorder. Neurology 2006, 66:845-851.
107. Postuma R.B., Gagnon J.F., Vendette M., et al. Idiopathic REM sleep behavior disorder in the transition to degenerative disease. Mov Disord 2009, 24:2225-2232.
108. Przuntek H., Müller T., Riederer P. Diagnostic staging of Parkinson's disease: conceptual aspects. J Neural Transm 2004, 111:201-216.
109. Rascol O. The pharmacological therapeutic management of levodopa-induced dyskinesias in patients with Parkinson's disease. J Neurol 2000, 247:II51-II57.
110. Riederer P., Wuketich S. Time course of nigrostriatal degeneration in parkinson's disease. A detailed study of influential factors in human brain amine analysis. J Neural Transm 1976, 38:277-301.
111. Riederer P., Gerlach M., Müller T., et al. Relating mode of action to clinical practice: dopaminergic agents in Parkinson's disease. Parkinsonism Relat Disord 2007, 13:466-479.
112. Ross G.W., Abbott R.D., Petrovitch H., et al. Relationship between caffeine intake and parkinson disease. JAMA 2000, 284:1378-1379.
113. Russ H., Müller T., Woitalla D., et al. Detection of tolcapone in the cerebrospinal fluid of parkinsonian subjects. Naunyn Schmiedebergs Arch Pharmacol 1999, 360:719-720.
114. Rye D.B. Sleepiness and unintended sleep in Parkinson's disease. Curr Treat Options Neurol 2003, 5:231-239.
115. Sabate M., Gonzalez I., Ruperez F., et al. Obstructive and restrictive pulmonary dysfunctions in Parkinson's disease. J Neurol Sci 1996, 138:114-119.
116. Samanta J., Hauser R.A. Duodenal levodopa infusion for the treatment of Parkinson's disease. Expert Opin Pharmacother 2007, 8:657-664.
117. Schrag A., Ben Shlomo Y., Quinn N. How valid is the clinical diagnosis of Parkinson's disease in the community?. J Neurol Neurosurg Psychiatry 2002, 73:529-534.
118. Shiba M., Bower J.H., Maraganore D.M., et al. Anxiety disorders and depressive disorders preceding Parkinson's disease: a case-control study. Mov Disord 2000, 15:669-677.
119. Simola N., Morelli M., Pinna A. Adenosine A2A receptor antagonists and Parkinson's disease: state of the art and future directions. Curr Pharm Des 2008, 14:1475-1489.
120. Stiasny-Kolster K., Doerr Y., Moller J.C., et al. Combination of 'idiopathic' REM sleep behaviour disorder and olfactory dysfunction as possible indicator for alpha-synucleinopathy demonstrated by dopamine transporter FP-CIT-SPECT. Brain 2005, 128:126-137.
121. Stocchi F., Ruggieri S., Vacca L., et al. Prospective randomized trial of lisuride infusion versus oral levodopa in patients with Parkinson's disease. Brain 2002, 125:2058-2066.
122. Sulzer D. Alpha-synuclein and cytosolic dopamine: stabilizing a bad situation. Nat Med 2001, 7:1280-1282.
123. Tanner C.M., Ross G.W., Jewell S.A., et al. Occupation and risk of parkinsonism: a multicenter case-control study. Arch Neurol 2009, 66:1106-1113.
124. Tiraboschi P., Hansen L.A., Alford M., et al. Cholinergic dysfunction in diseases with Lewy bodies. Neurology 2000, 54:407-411.
125. Tissingh G., Berendse H.W., Bergmans P., et al. Loss of olfaction in de novo and treated Parkinson's disease: possible implications for early diagnosis. Mov Disord 2001, 16:41-46.
126. Weaver F.M., Follett K., Stern M., et al. Bilateral deep brain stimulation vs best medical therapy for patients with advanced Parkinson disease: a randomized controlled trial. JAMA 2009, 301:63-73.
127. Weiner W.J. What do clinical trials tell us about treating patients. Parkinsonism Relat Disord 2009, 15:S34-S37.
128. Weintraub D. Dopamine and impulse control disorders in Parkinson's disease. Ann Neurol 2008, 64:S93-S100.
129. Werber E.A., Rabey J.M. The beneficial effect of cholinesterase inhibitors on patients suffering from Parkinson's disease and dementia. J Neural Transm 2001, 108:1319-1325.
130. Winge K., Skau A.M., Stimpel H., et al. Prevalence of bladder dysfunction in Parkinsons disease. Neurourol Urodyn 2006, 25:116-122.
131. Witjas T., Kaphan E., Azulay J.P., et al. Nonmotor fluctuations in Parkinson's disease: frequent and disabling. Neurology 2002, 59:408-413.
132. Witjas T., Baunez C., Henry J.M., et al. Addiction in Parkinson's disease: impact of subthalamic nucleus deep brain stimulation. Mov Disord 2005, 20:1052-1055.
133. Witt K., Daniels C., Reiff J., et al. Neuropsychological and psychiatric changes after deep brain stimulation for Parkinson's disease: a randomised, multicentre study. Lancet Neurol 2008, 7:605-614.
134. Woitalla D., Goetze O., Kim J.I., et al. Levodopa availability improves with progression of Parkinson's disease. J Neurol 2006, 53:1221-1226.
135. Wolters E.C. Variability in the clinical expression of Parkinson's disease. J Neurol Sci 2008, 266:197-203.
136. Wolters E.C., Braak H. Parkinson's disease: premotor clinico-pathological correlations. J Neural Transm Suppl 2006, 70:309-319.
137. Wolters E.C., Francot C., Bergmans P., et al. Preclinical (premotor) Parkinson's disease. J Neurol 2000, 247:II103-II109.
138. Wolters E.C., van der Werf Y.D., van den Heuvel O.A. Parkinson's disease-related disorders in the impulsive-compulsive spectrum. J Neurol 2008, 255:48-56.
139. Wszolek Z.K., Markopoulou K. Olfactory dysfunction in Parkinson's disease. Clin Neurosci 1998, 5:94-101.
140. Yamamura S., Ohoyama K., Hamaguchi T., et al. Effects of quetiapine on monoamine, GABA, and glutamate release in rat prefrontal cortex. Psychopharmacology (Berl) 2009, 206:243-258.
141. York M.K., Dulay M., Macias A., et al. Cognitive declines following bilateral subthalamic nucleus deep brain stimulation for the treatment of Parkinson's disease. J Neurol Neurosurg Psychiatry 2008, 79:789-795.
142. Zahodne L.B., Okun M.S., Foote K.D., et al. Cognitive declines one year after unilateral deep brain stimulation surgery in Parkinson's disease: a controlled study using reliable change. Clin Neuropsychol 2009, 23:385-405.